Wednesday announced the pricing of underwritten public offering of around 4.4 million shares at $17 per share, ...

Shares of the international gene therapy developer uniQure (NASDAQ: QURE) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the ...

Qure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its underwritten public offering of 4 ...

LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing ...

Qure (NASDAQ:QURE – Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $18.05, but opened at $17.55. uniQure shares last traded at $17.73, with ...

FDA agrees that the composite Unified Huntington’s Disease Rating Scale (cUHDRS) may serve as an intermediate clinical endpoint for Accelerated Approval ~ As part of uniQure’s ...

Bullish option flow detected in uniQure (QURE) with 6,527 calls trading, 2x expected, and implied vol increasing over 14 points to 82.58%. Jan-25 17 calls and Jan-25 22 calls are the most active ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

Raymond James analyst Danielle Brill upgraded uniQure (QURE) to Strong Buy from Outperform with a price target of $52, up from $20. Discover top-rated stocks from highly ranked analysts with ...

Qure (QURE) announced that it has commenced an underwritten public offering of its ordinary shares and pre-funded warrants to purchase its ...

EST uniQure (QURE) files automatic mixed securities shelfStay Ahead of the Market:Discover outperforming stocks and invest smarter with ...

LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...